These are the five stocks to watch heading into Tuesday, November 17, 2026. Each received a bullish rating change on Monday, November 16. Stocks were mixed on Friday, November 13, as chip stocks extended their slide after Nvidia CEO Jensen Huang's resignation. The S&P 500 fell 30.73 points, or 0.4%, to 7,561.67. The Dow Jones Industrial Average rose 50.46 points, or 0.1%, to 52,347.55, and the Nasdaq Composite fell 0.9% to 25,136.27. Even so, all three indexes posted gains of more than 2% for the week ended November 13. Technology shares led declines again on November 16, as investors prepared for Nvidia's quarterly results on November 17 and Anthropic's planned initial public offering.
The five ideas below span health insurance, cruise travel, steel, industrial equipment, and business payments software. Editorial notes only, not investment advice.
Humana (HUM) β RBC Capital Upgrades the Medicare Advantage Insurer
RBC Capital analyst Ben Hendrix upgraded Humana from Sector Perform to Outperform on Monday and raised his price target to $563 from $415. He cited the company's "impressive Stars turnaround," along with disciplined medical cost management amid 23% growth in individual Medicare Advantage membership this year. Humana's third-quarter adjusted loss of $0.70 per share was narrower than the $1.00 loss analysts expected, and the company raised its 2026 adjusted earnings guidance to at least $9.50 per share. In our view, improved quality ratings give Humana a clearer path to restoring margins.
Shares traded near $458.85 during Monday's session, up about 1.97%, giving Humana a market capitalization near $55.1 billion. The 52-week range runs from $163.11 to $461.00, and the trailing price-to-earnings multiple is 44.65.
Consensus reads buy, with 12 of 20 tracked firms bullish, seven neutral, and one bearish. The average price target of $452.55 sits slightly below the share price, so the RBC target, which implies about 23% upside, is the more relevant marker. Wells Fargo's Stephen Baxter raised his target to $602 from $502 on November 12.
Risks: TD Cowen's Ryan Langston rates the stock Hold with a $430 target, and JPMorgan's Lisa Gill is Neutral at $484. Medicare reimbursement policy and medical cost trends remain factors to monitor.
Viking Holdings (VIK) β Mizuho Double Upgrades the Cruise Operator
Mizuho analyst Ben Chaiken upgraded Viking Holdings two notches, from Underperform to Outperform, and raised his price target to $120 from $82 ahead of the company's third-quarter report. He said the shares have lagged Royal Caribbean and Carnival over the past six months, largely because of low river levels in Europe, which he views as transitory. Mizuho expects a material impact on 2027 and 2028 results but sees "significant upside to numbers" in 2029. In our view, ocean cruises, about half of Viking's business, help offset the river disruptions.
Shares traded near $89.44 during Monday's session, down about 0.48%, giving Viking a market capitalization near $39.9 billion. The 52-week range runs from $56.67 to $110.09, and the trailing price-to-earnings multiple is 29.53.
Consensus reads strong buy, with 13 of 15 tracked firms bullish. The average price target of $105.20 implies roughly 18% upside, and the Mizuho target implies about 34%.
Risks: Wells Fargo's Trey Bowers cut his target to $118 from $128 on November 9, and Morgan Stanley's Stephen Grambling is Equal Weight at $94. River conditions and quarterly guidance remain factors to monitor.
Nucor (NUE) β UBS Upgrades the Largest U.S. Steelmaker on Cash Flow
UBS analyst Andrew Jones upgraded Nucor from Neutral to Buy on Monday and raised his price target to $307 from $256. He noted that hot-rolled coil prices have risen about $250 per short ton since June while the shares stayed broadly flat. UBS forecasts free cash flow yields of 8% to 11% from 2027 through 2030 as capital spending moderates, which could support larger buybacks. Third-quarter results for Nucor's downstream Products segment rose 32% from the prior quarter, with backlogs extending into mid-2027. In our view, data center and reshoring demand adds durability beyond the steel price cycle.
Shares traded near $253.67 during Monday's session, up about 0.77%, giving Nucor a market capitalization near $57.1 billion. The 52-week range runs from $146.00 to $287.70, and the trailing price-to-earnings multiple is 16.14.
Consensus reads strong buy, with 10 of 11 tracked firms bullish and one neutral. The average price target of $286.27 implies roughly 13% upside, and the UBS target implies about 21%. Barclays' Richard Garchitorena raised his target to $345 from $320 on November 12.
Risks: Steel prices could normalize if imports rise. Tariff policy and execution on the West Virginia mill ramp remain factors to monitor.
SPX Technologies (SPXC) β TD Cowen Upgrades the HVAC and Detection Equipment Maker
TD Cowen analyst Joe Giordano upgraded SPX Technologies from Hold to Buy on Monday, while lowering his price target to $200 from $225. "The froth has been replaced with AI fear and margins have been reset to reflect higher costs," he wrote, calling it "a more palatable entry for the same attractive growth profile." In our view, the reset valuation makes the growth story more balanced.
Shares traded near $146.82 during Monday's session, down about 5.17%, giving SPX a market capitalization near $7.4 billion. The 52-week range runs from $137.86 to $251.08, and the trailing price-to-earnings multiple is 24.88.
Consensus reads strong buy, with all seven tracked firms bullish. The average price target of $236.57 includes older, higher targets, so the TD Cowen target, which implies about 36% upside, is a more current marker. Oppenheimer's Bryan Blair rates the stock Outperform at $260.
Risks: JPMorgan's Julian Mitchell cut his target to $190 from $225 on November 11, and the shares fell sharply on November 16. Data center spending and cost pressures remain factors to monitor.
BILL Holdings (BILL) β William Blair Upgrades the Business Payments Platform
William Blair analyst Andrew Jeffrey upgraded BILL Holdings from Market Perform to Outperform on Monday, without a price target. "We see Bill positioned for improving monetization and more robust-than-expected margin expansion," the firm wrote. William Blair cited the company's push toward larger small and midsize businesses, plus a restructured sales team with new product and revenue chiefs. In our view, BILL offers rare pure-play exposure to business-to-business payments.
Shares traded near $57.28 during Monday's session, up about 5.14%, giving BILL a market capitalization near $4.9 billion. The 52-week range runs from $31.41 to $58.47, and the trailing price-to-earnings multiple is 109.27.
Consensus reads buy, with 12 of 20 tracked firms bullish and eight neutral. The average price target of $59.55 implies roughly 4% upside. TD Cowen's $66 target from November 9 implies about 15%.
Risks: Morgan Stanley's Keith Weiss rates the stock Equal Weight at $64. William Blair acknowledged longer-term competitive concerns, and shares trade near their 52-week high, which remain factors to monitor.
Found this helpful? Share it with others.